In addition, it was demonstrated that GLP-1 analogs and cAMP inducers enhance frataxin protein expression in in vitro and in vivo FRDA models and in a pilot study with FRDA patients (Igoillo-Esteve et al., 2019). Here, FXN is linked to Friedreich ataxia.